MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...

MSD has only just completed its $10 billion takeover of Verona Pharma, but is still on the hunt for more bolt-on acquisitions to flesh out its pipeline, according to chief executive Rob Davis. On the ...